Assessing the economic value of antihypertensive medications.
OBJECTIVE
To assess the economic value of antihypertensive medications by comparing the likelihood of coronary heart disease and stroke events and subsequent event treatment costs.


METHODS
Duration of blood pressure reduction was used to profile event risk reduction of three antihypertensive medications.


METHODS
We used clinical data to determine the duration of blood pressure reduction achieved with use of two angiotensin converting enzyme inhibitors and one angiotensin II receptor antagonist. We then used trough-to-peak ratios to calculate the reduction in risk of coronary heart disease and stroke events associated with each medication.


RESULTS
Across a number of different event treatment cost and population size estimates, the economic value of different medications can be assessed.


CONCLUSIONS
Our method for assessing the economic value of antihypertensive medications can be applied to other drug classes and can be further refined by integrating patient population and other risk-related data.
Roth
M S
MS
Darla Moore School of Business, University of South Carolina, Columbia 29208, USA.
Davenport
R C
RC
Simpson
W
W
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics*; D000959:Antihypertensive Agents / Q000191:economics*; D002561:Cerebrovascular Disorders / Q000517:prevention & control; D003327:Coronary Disease / Q000517:prevention & control; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000191:economics*; D008329:Managed Care Programs / Q000191:economics; D014481:United States
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents